Screener
Aquestive Therapeutics, Inc. AQST Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues | $13,819 | $10,003 | $28,265 | $18,723 |
| Costs and expenses: | ||||
| Manufacture and supply | 4,017 | 4,561 | 7,486 | 8,213 |
| Research and development | 3,962 | 4,105 | 8,166 | 9,466 |
| Selling, general and administrative | 14,063 | 12,705 | 25,040 | 31,777 |
| Total costs and expenses | 22,042 | 21,371 | 40,692 | 49,456 |
| Loss from operations | (8,223) | (11,368) | (12,427) | (30,733) |
| Other income/(expenses): |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s total revenue?
- Aquestive Therapeutics, Inc. (AQST) reported total revenue of $13.82M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s total revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s total revenue increased by 38.1% year-over-year, from $10M to $13.82M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s total revenue has grown at a -3.2% compound annual growth rate (CAGR), from $50.83M to $44.55M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Aquestive Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude